Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Daelman, A. Maîtrot, A. Maarouf, M. Chaunu, C. Papeix, A. Tourbah (2012)
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawalMultiple Sclerosis Journal, 18
P. Sørensen, A. Bertolotto, G. Edan, G. Giovannoni, R. Gold, E. Havrdová, L. Kappos, B. Kieseier, X. Montalban, T. Olsson (2012)
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumabMultiple Sclerosis Journal, 18
R. Naismith, D. Bourdette (2011)
Interruption of natalizumab therapy for multiple sclerosisNeurology, 76
T. West, B. Cree (2010)
Natalizumab dosage suspension: Are we helping or hurting?Annals of Neurology, 68
J. Killestein, A. Vennegoor, E. Strijbis, A. Seewann, B. Oosten, B.M.J. Uitdehaag, C. Polman (2010)
Natalizumab drug holiday in multiple sclerosis: Poorly ToleratedAnnals of Neurology, 68
G. Borriello, L. Prosperini, C. Mancinelli, C. Giannì, F. Fubelli, C. Pozzilli (2012)
Pulse monthly steroids during an elective interruption of natalizumab: a post‐marketing studyEuropean Journal of Neurology, 19
S. Jander, B. Turowski, B. Kieseier, H. Hartung (2012)
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimodMultiple Sclerosis Journal, 18
Augusto Miravalle, R. Jensen, R. Kinkel (2011)
Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.Archives of neurology, 68 2
(2012)
From natalizumab to fingolimod: an observational study of 32 patients
J. Havla, B. Tackenberg, K. Hellwig, I. Meinl, M. Krumbholz, F. Seitz, C. Eienbröker, R. Gold, R. Hohlfeld, I. Kleiter, T. Kümpfel (2013)
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosisJournal of Neurology, 260
M. Magraner, F. Coret, A. Navarre, I. Boscá, M. Simó, M. Escutia, Ana Bernad, L. Navarro, B. Casanova (2011)
Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational studyJournal of Neurology, 258
F. Rinaldi, D. Seppi, M. Calabrese, P. Perini, Paolo Gallo (2012)
Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findingsMultiple Sclerosis Journal, 18
RT Naismith, D Bourdette (2011)
Interruption of natalizumab therapy for multiple sclerosis: what are the risks?, 76
G. Borriello, L. Prosperini, F. Marinelli, F. Fubelli, C. Pozzilli (2011)
Observations during an elective interruption of natalizumab treatment: a post-marketing studyMultiple Sclerosis, 17
A. Laroni, Davide Brogi, V. Milesi, L. Abate, A. Uccelli, G. Mancardi (2013)
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruptionMultiple Sclerosis Journal, 19
Paul O'Connor, Andrew Goodman, L. Kappos, F. Lublin, Dh Miller, C. Polman, R. Rudick, W. Aschenbach, N. Lucas (2011)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology, 76
ImportanceThe safety and efficacy of switching from natalizumab to fingolimod have not yet been evaluated in a large cohort of patients with multiple sclerosis (MS) to our knowledge. ObjectiveTo collect data from patients with MS switching from natalizumab to fingolimod. Design, Setting, and ParticipantsThe Enquête Nationale sur l’Introduction du Fingolimod en Relais au Natalizumab (ENIGM) study, a survey-based, observational multicenter cohort study among MS tertiary referral centers. Participants were patients for whom a switch from natalizumab to fingolimod was planned. Clinical data were collected on natalizumab treatment, duration and management of the washout period (WP), and relapse or adverse events during the WP and after the initiation of fingolimod. Main Outcomes and MeasuresOccurrence of MS relapse during the WP or during a 6-month follow-up period after the initiation of fingolimod. ResultsThirty-six French MS tertiary referral centers participated. In total, 333 patients with MS switched from natalizumab to fingolimod after a mean of 31 natalizumab infusions (female to male ratio, 2.36; mean age, 41 years; and Expanded Disability Status Scale score at the initiation of natalizumab, 3.6). Seventy-one percent were seropositive for the JC polyomavirus. The Expanded Disability Status Scale score remained stable for patients receiving natalizumab. Twenty-seven percent of patients relapsed during the WP. A WP shorter than 3 months was associated with a lower risk of relapse (odds ratio, 0.23; P = .001) and with less disease activity before natalizumab initiation (P = .03). Patients who stopped natalizumab because of poor tolerance or lack of efficacy also had a higher risk of relapse (odds ratio, 3.20; P = .004). Twenty percent of patients relapsed during the first 6 months of fingolimod therapy. Three percent stopped fingolimod for efficacy, tolerance, or compliance issues. In the multivariate analysis, the occurrence of relapse during the WP was the only significant prognostic factor for relapse during fingolimod therapy (odds ratio, 3.80; P = .05). Conclusions and RelevanceIn this study, switching from natalizumab to fingolimod was associated with a risk of MS reactivation during the WP or shortly after fingolimod initiation. The WP should be shorter than 3 months.
JAMA Neurology – American Medical Association
Published: Apr 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.